Total Trades
Politicians Trading
Last Traded
Price history
Congressional Trades
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
Total Trades
Politicians Trading
Last Traded
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
$139.03updated Apr 14, 2026
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Total Trades
11
Politicians Trading
6
Last Traded
Jan 27, 2026
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Josh GottheimerD | Feb 26, 2026 | Jan 27, 2026 | Buy | $1,001 – $15,000 | -1.38% |
| Val T. HoyleD | Oct 10, 2025 | Sep 23, 2025 | Sell | $1,001 – $15,000 | +21.53% |
| Marjorie Taylor GreeneR | Jun 18, 2025 | Jun 6, 2025 | Buy | $1,001 – $15,000 | +23.63% |
| Josh GottheimerD | Jun 11, 2025 | May 14, 2025 | Sell | $1,001 – $15,000 | +41.32% |
| Jefferson ShreveR | Jun 22, 2025 | May 12, 2025 | Sell | $15,001 – $50,000 | +33.91% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 – $15,000 | +35.23% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 – $15,000 | +35.23% |
| John BoozmanR | May 14, 2025 | Apr 16, 2025 | Sell | $1,001 – $15,000 | +32.56% |
| Jefferson ShreveR | Apr 11, 2025 | Mar 31, 2025 | Buy | $15,001 – $50,000 | +24.08% |
| Carol D. MillerR | Apr 11, 2025 | Mar 10, 2025 | Buy | $1,001 – $15,000 | +18.62% |
| Josh GottheimerD | Apr 10, 2025 | Mar 7, 2025 | Buy | $1,001 – $15,000 | +18.41% |